Attilio Barretta

Attilio Barretta

Auto-generated profile, based on publicly available information

Attilio Barretta

Division of Urology IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in BJU International
Verified
Journal Article
Closed access
ABAttilio Barretta
Attilio Barretta
PPPietro Piazza
Pietro Piazza
CCCalogero Catanzaro
Calogero Catanzaro
AMAngelo Mottaran
Angelo Mottaran
MPMassimiliano Presutti
Massimiliano Presutti
RSRiccardo Schiavina
Riccardo Schiavina

24 March 2026 in BJU International
Verified
Journal Article
Open access
PDF file
MAMario De Angelis
Mario De Angelis
EBEdoardo Beatrici
Edoardo Beatrici
NPNatali Rodriguez Penaranda
Natali Rodriguez Penaranda
NFNicola Frego
Nicola Frego
SRStefano Resca
Stefano Resca
AMAlexandre Mottrie
Alexandre Mottrie
Objective: To evaluate the feasibility of adopting fluorescence confocal microscopy (FCM) for intraoperative assessment of positive surgical margins (PSMs) during robot‐assisted radical prostatectomy (RARP) in a real‐world clinical setting. Patients and Methods: We conducted a prospective observational study including consecutive patients undergoing RARP between October 2023 and November 2024 in whom intraoperative margin assessment was performed using FCM (Histolog® Scanner; SamanTree Medical SA, Lausanne, Switzerland). After exclusion of initial learning‐curve cases and non‐interpretable scans, a per‐patient analysis was performed. Prostate specimens were scanned ex vivo intraoperatively, and digital images were reviewed remotely and in real time by an experienced uropathologist blinded to final pathology. Final histopathological evaluation served as the reference standard. Diagnostic performance metrics included sensitivity, specificity, positive predictive value (PPV), negative PV (NPV), and overall accuracy, assessed both for any PSM and for clinically significant PSMs (≥3 mm). Results: A total of 101 patients were included in the final analysis. The median (interquartile range) overall time from prostate extraction to intraoperative report was 13 (6–16) min. At final pathology, 17 patients (17%) had PSMs. For detection of any PSM, FCM demonstrated a sensitivity of 88.2%, specificity of 91.7%, PPV of 68.2%, and NPV of 97.5%, with an overall diagnostic accuracy of 91.1%. When restricting the analysis to clinically significant PSMs (≥3 mm), diagnostic performance improved, with sensitivity, specificity, PPV, and NPV of 93.8%, 91.8%, 68.2%, and 98.7%, respectively, and an overall accuracy of 92.1%. Conclusions: Intraoperative surgical margin assessment using FCM is feasible and demonstrates good diagnostic accuracy compared with final histopathology, with rapid turnaround times compatible with routine surgical workflows. Diagnostic performance improves when clinically relevant PSM length thresholds are applied. Larger multicentre studies and randomised trials are warranted to determine whether FCM‐guided intraoperative decision‐making can improve oncological and functional outcomes after RARP.

13 January 2026 in BJU International
Verified
Journal Article
Closed access
FCFrancesco Cei
Francesco Cei
DCDaniele Cignoli
Daniele Cignoli
IFIrene Franco
Irene Franco
KRKoon Ho Rha
Koon Ho Rha
CWChristian Wagner
Christian Wagner
ALAlessandro Larcher
Alessandro Larcher

1 March 2026 in Journal of Endourology
Verified
Journal Article
Closed access
ABAttilio Barretta
Attilio Barretta
PPPietro Piazza
Pietro Piazza
ABAndrea Boccatonda
Andrea Boccatonda
ABAlice Brighenti
Alice Brighenti
CSCarla Serra
Carla Serra
RSRiccardo Schiavina
Riccardo Schiavina
Background and Aim: Percutaneous radiofrequency ablation (RFA) is an increasingly adopted treatment for small solid renal masses. However, its safety and oncological effectiveness in complex renal cysts, classified as Bosniak III and IV, remain poorly characterized. We aimed to evaluate oncological outcomes and safety of RFA in patients with Bosniak III-IV cysts. Methods: We retrospectively identified patients who underwent ultrasound-guided percutaneous RFA for Bosniak III-IV renal cysts at our institute between June 2017 and February 2025. Clinical, radiological, histological, and functional data were collected. Technical success was defined as the absence of enhancement on intra- and postprocedural contrast-enhanced ultrasound. Results: Overall, 34 patients underwent RFA for 38 cT1a complex renal cysts (mean diameter 2.11 ± 0.7 cm): 8 (21.1%) were Bosniak III and 30 (78.9%) Bosniak IV. Two patients with Bosniak III cyst were subsequently excluded from oncological analyses because of benign or nondiagnostic histology report. Technical success was achieved in 100% of cases. Postprocedural laboratory values showed Δ creatinine 0.02 mg/dL (interquartile range [IQR]: 0.01–0.05; p = 0.001), Δ estimated glomerular filtration rate −0.80 mL/min/1.73 m 2 (IQR: −2.0–0.0; p = 0.001), and Δ hemoglobin −0.2 g/dL (IQR: −1.0–0.0; p = 0.001). Postprocedural complications were observed in 2/34 patients (5.8%), both involving hemorrhages, one of which required transarterial embolization (Clavien–Dindo grade III). At a median follow-up of 62.5 months (IQR: 18–72.5), local recurrence occurred in 2/32 patients (6.2%). No cases of systemic progression or cancer-specific mortality rate were observed. Conclusion: Ultrasound-guided RFA appears to be a safe and feasible nephron-sparing option for the management of Bosniak III-IV renal cystic lesions in selected patients.

15 May 2026 in BJU International
Verified
Journal Article
Closed access
CBClaudio Brancelli
Claudio Brancelli
MAMario De Angelis
Mario De Angelis
EBEdoardo Beatrici
Edoardo Beatrici
ABAttilio Barretta
Attilio Barretta
STSara Tamburini
Sara Tamburini
AMAlexandre Mottrie
Alexandre Mottrie

1 October 2025 in JCO Oncology Advances
Verified
Journal Article
Closed access
CRChiara Re
Chiara Re
ALAlessandro Larcher
Alessandro Larcher
FCFrancesco Cei
Francesco Cei
FBFederico Belladelli
Federico Belladelli
LSLucia Salerno
Lucia Salerno
NTNazario Tenace
Nazario Tenace
PURPOSE: Von Hippel-Lindau (VHL) disease is a rare genetically inherited disorder and represents the most frequent cause of hereditary renal cancer (RC). Depression and quality of life (QoL) are often neglected or underreported issues in individuals affected by VHL disease. We sought to investigate QoL items in patients with VHL disease versus patients with sporadic RC (spRC) in a comparative analysis using patient-reported outcome measures (PROMs). MATERIALS AND METHODS: In an institutional prospective VHL program, 30 VHL patients with RC have been enrolled. The comparator was a cohort of 393 patients surgically treated for spRC. To prospectively evaluate PROMs about depression and sexual functioning, all patients completed the Beck Depression Inventory scale, the Female Sexual Function Index for female, and the International Index of Erectile Function for male patients, respectively. Multivariable linear regression analysis tested the association between VHL disease or spRC and the study outcomes. RESULTS: Overall, 30 (7%) and 393 (93%) patients had VHL disease and spRC, respectively. At multivariable linear regression analysis, patients with VHL disease were more prone to depression according to a higher Beck Depression Inventory score (estimate 8.8; P < .0001); this difference was more pronounced in older patients. Conversely, VHL and spRC groups did not differ in terms of sexual functioning. CONCLUSION: Patients diagnosed with hereditary RC are more prone to depression compared with patients diagnosed with spRC. Conversely, the two groups did not differ in terms of sexual well-being. These novel findings highlight the clinical importance of psychological counseling throughout the management workup of patients with lifelong hereditary disorders.